{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:17:05Z","timestamp":1773836225711,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":300,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL103988"],"award-info":[{"award-number":["R01HL103988"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000038"],"award-info":[{"award-number":["UL1 TR000038"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.curtheres.2025.100814","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:52:41Z","timestamp":1761897161000},"page":"100814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure"],"prefix":"10.1016","volume":"103","author":[{"given":"Randal","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Norcliffe-Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikoa","family":"Jeschke-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta M.","family":"Goldring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carey","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manushree","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Reyentovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2340-2021","authenticated-orcid":false,"given":"Stuart D.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2025.100814_bib0001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.1991.03470050093029","article-title":"Pyridostigmine used as a nerve agent pretreatment under wartime conditions","volume":"266","author":"Keeler","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.curtheres.2025.100814_bib0002","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.curtheres.2025.100814_bib0003","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2165\/00003088-198611030-00005","article-title":"Clinical pharmacokinetics of cholinesterase inhibitors","volume":"11","author":"Aquilonius","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.curtheres.2025.100814_bib0004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.etap.2004.12.048","article-title":"Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of a common mechanism of action","volume":"19","author":"Pope","year":"2005","journal-title":"Environ Toxicol Pharmacol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bcp.2018.01.044","article-title":"Cholinesterases and the fine line between poison and remedy","volume":"153","author":"Pope","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0006","unstructured":"US Food and Drug Administration. Bausch Health Companies Inc. or its affiliates. Pyridostigmine Bromide Oral Tablets [package insert]. Revised December 2020. https:\/\/pi.bauschhealth.com\/globalassets\/BHC\/PI\/Mestinon-PI.pdf. Accessed July 2024."},{"key":"10.1016\/j.curtheres.2025.100814_bib0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0002-8703(03)00319-3","article-title":"Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure","volume":"146","author":"Behling","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.curtheres.2025.100814_bib0008","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/hrt.2003.028167","article-title":"Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia","volume":"90","author":"Castro","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.curtheres.2025.100814_bib0009","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1161\/CIRCULATIONAHA.104.497594","article-title":"Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome","volume":"111","author":"Raj","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.curtheres.2025.100814_bib0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1590\/S0066-782X2001000400002","article-title":"Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine","volume":"76","author":"Serra","year":"2001","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0011","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.curtheres.2025.100814_bib0012","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0013","first-page":"R310","article-title":"Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure","volume":"268","author":"Kinugawa","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0014","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1152\/jappl.1998.84.4.1234","article-title":"Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure","volume":"84","author":"Ishise","year":"1998","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.curtheres.2025.100814_bib0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0735-1097(91)90602-6","article-title":"Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure","volume":"18","author":"Binkley","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0016","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cardfail.2009.06.437","article-title":"Post-exercise heart rate recovery independently predicts mortality risk in patients with chronic heart failure","volume":"15","author":"Tang","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.curtheres.2025.100814_bib0017","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0002-9149(87)90795-8","article-title":"Decreased heart rate variability and its association with increased mortality after acute myocardial infarction","volume":"59","author":"Kleiger","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0018","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/CIRCULATIONAHA.107.760405","article-title":"Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy","volume":"118","author":"Olshansky","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.curtheres.2025.100814_bib0019","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/heart.89.8.854","article-title":"Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure","volume":"89","author":"Androne","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.curtheres.2025.100814_bib0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0733-8651(05)70223-X","article-title":"Exercise and autonomic function in health and cardiovascular disease","volume":"19","author":"Rosenwinkel","year":"2001","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.curtheres.2025.100814_bib0021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1054\/jcaf.2003.47","article-title":"Decreased heart rate recovery after exercise in patients with congestive heart failure: effect of beta-blocker therapy","volume":"9","author":"Racine","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.curtheres.2025.100814_bib0022","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0735-1097(00)00900-1","article-title":"Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure","volume":"36","author":"Mortara","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0023","doi-asserted-by":"crossref","first-page":"H86","DOI":"10.1152\/ajpheart.01339.2006","article-title":"Effect of acetylcholinesterase inhibition with pyridostigmine on cardiac parasympathetic function in sedentary adults and trained athletes","volume":"293","author":"Dewland","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0024","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0735-1097(94)90150-3","article-title":"Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure","volume":"24","author":"Imai","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM199910283411804","article-title":"Heart-rate recovery immediately after exercise as a predictor of mortality","volume":"341","author":"Cole","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2025.100814_bib0026","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIR.0b013e31829b5b44","article-title":"Exercise standards for testing and training: a scientific statement from the American Heart Association","volume":"128","author":"Fletcher","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.curtheres.2025.100814_bib0027","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fpubh.2017.00258","article-title":"An overview of heart rate variability metrics and norms","volume":"5","author":"Shaffer","year":"2017","journal-title":"Front Public Health"},{"key":"10.1016\/j.curtheres.2025.100814_bib0028","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00204-006-0144-7","article-title":"Effects of combined, multiple stressors on pyridostigmine-induced acute toxicity in rats","volume":"81","author":"Baireddy","year":"2007","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0029","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/toxsci\/69.1.157","article-title":"Acute and repeated restraint stress have little effect on pyridostigmine toxicity or brain regional cholinesterase inhibition in rats","volume":"69","author":"Song","year":"2002","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.curtheres.2025.100814_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0300-483X(02)00089-6","article-title":"Neither forced running nor forced swimming affect acute pyridostigmine toxicity or brain-regional cholinesterase inhibition in rats","volume":"176","author":"Tian","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.curtheres.2025.100814_bib0031","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/10915810290096595","article-title":"Standardization of clinical cholinesterase measurements","volume":"21","author":"Wilson","year":"2002","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0032","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0378-4347(93)E0430-X","article-title":"Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection","volume":"653","author":"Holmes","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.curtheres.2025.100814_bib0033","first-page":"1102","article-title":"Side effects of low-dose pyridostigmine bromide are not related to cholinesterase inhibition","volume":"72","author":"Cook","year":"2001","journal-title":"Aviat Space Environ Med"},{"key":"10.1016\/j.curtheres.2025.100814_bib0034","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City cardiomyopathy questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.curtheres.2025.100814_bib0035","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1440-1681.12773","article-title":"Subacute pyridostigmine exposure increases heart rate recovery and cardiac parasympathetic tone in rats","volume":"44","author":"Bharadwaj","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02280691","article-title":"Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress","volume":"9","author":"N\u00f3brega","year":"1999","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.curtheres.2025.100814_bib0037","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02317797","article-title":"Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects","volume":"11","author":"N\u00f3brega","year":"2001","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.curtheres.2025.100814_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/j.1552-4604.1998.tb04420.x","article-title":"Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans","volume":"38","author":"Marino","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0039","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00213-002-1074-6","article-title":"Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study","volume":"162","author":"Cook","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.curtheres.2025.100814_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2005.10.031","article-title":"Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman","author":"Gordon","year":"2005","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.curtheres.2025.100814_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0300-483X(82)90021-X","article-title":"Tolerance to anticholinesterase compounds in mammals","volume":"25","author":"Costa","year":"1982","journal-title":"Toxicology"},{"key":"10.1016\/j.curtheres.2025.100814_bib0042","doi-asserted-by":"crossref","first-page":"H1632","DOI":"10.1152\/ajpheart.01051.2002","article-title":"Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity","volume":"285","author":"Dunlap","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0043","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0091-3057(03)00022-4","article-title":"Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice","volume":"74","author":"Li","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.curtheres.2025.100814_bib0044","doi-asserted-by":"crossref","first-page":"H1780","DOI":"10.1152\/ajpheart.00430.2004","article-title":"Prevention of diminished parasympathetic control of the heart in experimental heart failure","volume":"287","author":"Bibevski","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0045","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.90.5.2213","article-title":"Alterations in muscarinic K+ channel response to acetylcholine and to G protein-mediated activation in atrial myocytes isolated from failing human hearts","volume":"90","author":"Koumi","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.curtheres.2025.100814_bib0046","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1172\/JCI113528","article-title":"Impaired cardiac muscarinic receptor function in dogs with heart failure","volume":"81","author":"Vatner","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.curtheres.2025.100814_bib0047","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032533","article-title":"Interleukin 17A contributes to blood-brain barrier disruption of hypothalamic paraventricular nucleus in rats with myocardial infarction","volume":"13","author":"Yu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.curtheres.2025.100814_bib0048","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCRESAHA.107.148940","article-title":"Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction","volume":"101","author":"Yu","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.curtheres.2025.100814_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.837723","article-title":"New insights into the role of inflammation in the brain in heart failure","volume":"13","author":"Badoer","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.curtheres.2025.100814_bib0050","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1038\/s41598-021-89104-8","article-title":"Cholinergic stimulation with pyridostigmine modulates a heart-spleen axis after acute myocardial infarction in spontaneous hypertensive rats","volume":"11","author":"Bandoni","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.curtheres.2025.100814_bib0051","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41598-019-38841-y","article-title":"Cholinergic stimulation by pyridostigmine bromide before myocardial infarction prevent cardiac and autonomic dysfunction","volume":"9","author":"Barboza","year":"2019","journal-title":"Sci Rep"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:02:16Z","timestamp":1773824536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X25000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":51,"alternative-id":["S0011393X25000396"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100814","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100814"}}